Global Gene Editing Market Report to 2031 – Expanding Synthetic Gene Demand in Various Biotechnology Areas Has Fueled Growth – ResearchAndMarkets.com

Global Gene Editing Market Report to 2031 - Expanding Synthetic Gene Demand in Various Biotechnology Areas Has Fueled Growth - ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Gene Editing Market By Technology, By Application, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031” report has been added to ResearchAndMarkets.com’s offering.

The global gene editing market was valued at $3,886.34 million in 2021, and is projected to reach $7,437.47 million by 2031, registering a CAGR of 6.7% from 2022 to 2031.

Gene editing (also known as genome editing) refers to a set of technologies that allows scientists to alter an organism’s DNA. These technologies allow for the addition, removal, or modification of genetic material at specific points in the genome. There have been several ways to develop genome editing. CRISPR-Cas9, which stands for clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9, is one of the most well-known techniques.

The CRISPR-Cas9 system has sparked a lot of interest in the scientific community as it is faster, cheaper, more accurate, and more efficient than existing genome editing approaches. CRISPR-Cas9 is based on a naturally occurring genome editing technology used by bacteria to defend themselves. When bacteria are infected with viruses, they capture small fragments of the virus’s DNA and insert them into their own DNA in a specific way to form CRISPR arrays. Bacteria can ‘remember’ viruses, thanks to CRISPR arrays (or closely related ones).

If the viruses resurface, the bacteria create RNA segments from CRISPR arrays that detect and attach to specific sections of the viruses’ DNA. The bacteria then employ Cas9 or a similar enzyme to rip the virus’s DNA apart, rendering it inoperable. This immune defense mechanism was modified to modify DNA by researchers. They make a small piece of RNA with a short ‘guide’ sequence that connects (binds) to a specific target sequence in a cell’s DNA, similar to the RNA segments produced by bacteria using the CRISPR array.

This guide RNA binds to the Cas9 enzyme as well. When the guide RNA is injected into cells, it detects the desired DNA sequence, and the Cas9 enzyme cuts the DNA at the desired position, similar to how bacteria do it. Although Cas9 is the most commonly employed enzyme, other enzymes (such as Cpf1) can also be used. Researchers employ the cell’s own DNA repair mechanism to add or delete portions of genetic material, or to make modifications after the DNA has been cut.

Factors such as increased adoption of CRISPR genome editing technology along with expanding synthetic gene demand in various biotechnology areas has fueled the growth of the gene editing market. Furthermore, due to the growing uses of genome editing technologies, the industry is seeing increased competition among market competitors. The highly flexible CRISPR technique has gotten a lot of attention lately. For example, Vertex Pharmaceuticals paid CRISPR Therapeutics $900 million in April 2021 to develop, manufacture, and market CRISPR-Cas9 gene-edited treatment for beta-thalassemia and sickle-cell disease. Market growth is expected to be aided by such activities. Furthermore, the industry is being driven by the development of CRISPR-based innovative diagnostic tools to alleviate the negative effects of the COVID-19 pandemic.

Major key players that operate in the global gene editing market are Addgene, Allele Biotech, Bio-Rad Laboratories, CRISPR Therapeutics, General Electric, OriGene Technologies, Precision Biosciences, Takara Biotech, Thermofischer Scientific Inc., and Transposagen Biopharma Inc.

Key Benefits

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gene editing market analysis from 2021 to 2031 to identify the prevailing gene editing market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the gene editing market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global gene editing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Technology

Zinc Finger Nucleases (ZFNs)

CRISPR-Cas9 Gene Editing

Restriction Enzymes

Others

Transcription Activator-Like Effector-based Nucleases (TALENs)

By Application

Drug development

Others

Gene editing

Cell Line Engineering

Animal Genetic Engineering

Plant Genetic Engineering

By End User

Biotechnology and Pharmaceutical Companies

Academic and Government Research Institutes

Contract Research Organizations

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

Australia

India

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

Key Market Players

Addgene

Allele Biotech

Bio-Rad

Takara Bio

CRISPR Therapeutics

OriGene Technologies

Precision Biosciences

GE Healthcare

Merck KGaA

ThermoFisherScientific Inc.

For more information about this report visit https://www.researchandmarkets.com/r/bos5mb

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.